Predicting the response of patients with advanced urothelial cancer to methotrexate, vinblastine, Adriamycin, and cisplatin (MVAC) after the failure of gemcitabine and platinum (GP)

BACKGROUND: Platinum-based systemic chemotherapy is the treatment of choice for patients with advanced urothelial carcinoma (UC). Although no chemotherapeutic regimen is established as a second-line therapy, recent studies reported that methotrexate, vinblastine, Adriamycin and cisplatin (MVAC) elic...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Ki Hong, Hong, Sung Joon, Han, Kyung Seok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624663/
https://www.ncbi.nlm.nih.gov/pubmed/26506914
http://dx.doi.org/10.1186/s12885-015-1825-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624663/
https://www.ncbi.nlm.nih.gov/pubmed/26506914
http://dx.doi.org/10.1186/s12885-015-1825-5

Ejemplares similares